Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study
Status:
Recruiting
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
This phase II study will evaluate dostarlimab with a watch-and-wait approach for patients
with localized mismatch repair deficiency (dMMR)/microsatellite instability (MSI) gastric or
oeso-gastric junction adenocarcinoma.
The goal of the study is to determine whether the surgery could be avoided in patients with
localized dMMR/MSI-H gastric/OGJ adenocarcinoma with complete response at endoscopy and
biopsies free of tumoral cells after treatment with dostarlimab, with a watch-and-wait
approaches.
Phase:
Phase 2
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group